Alpha 2.0
Login Register
» Journals » Eur J Pharm Sci

European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences

The European Journal of Pharmaceutical Sciences is the official journal of the European Federation for Pharmaceutical Sciences. It publishes high-quality research articles, reviews, and commentaries in the field of pharmaceutical sciences. The journal covers a wide range of topics including drug discovery, drug delivery systems, pharmacokinetics, and pharmaceutical technology. It serves as a platform for researchers, scientists, and professionals to share their latest findings and advancements in the pharmaceutical field.
Details
Abbr. Eur J Pharm Sci
Start 1993
End Continuing
Frequency Fifteen no. a year, 2001-
p-ISSN 0928-0987
e-ISSN 1879-0720
Country Netherlands
Language English
Specialties Pharmacology
Chemistry
Metrics
h-index / Ranks: 1195 163
SJR / Ranks: 5768 752
CiteScore / Ranks: 1714 9.20
JIF / Ranks: 1820 4.6
Recent Articles
21.
Cancer-type OATP1B3-V1 is a functional plasma membrane transporter mediating increased uptake of chemotherapeutics in vitro and in vivo
Bakos E, Bujdoso-Szekely V, Patik I, Kiraly L, Lango T, Kozak E, et al.
Eur J Pharm Sci . 2025 Feb; :107046. PMID: 39983930
Cancer-type Organic anion transporting polypeptide 1B3, ct-OATP1B3-V1 is a tumor-specific isoform of liver-type OATP1B3 (Lt-OATP1B3). Ct-OATP1B3-V1 is identical with liver-specific Lt-OATP1B3 except it lacks the first 28 amino acids. Although...
22.
Dapagliflozin in diabetic kidney disease patients with different filtration status
Yang Y, Li M, Zou H, Yang P, Wang L, Xu G
Eur J Pharm Sci . 2025 Feb; 207:107045. PMID: 39961418
Background: Few studies have discussed the effects and mechanism of dapagliflozin on diabetic kidney disease (DKD) with different glomerular filtration rate (GFR) and systolic blood pressure (SBP). This study aimed...
23.
CRISPR/Cas9 based knockout of lncRNA MALAT1 attenuates TGF-β1 induced Smad 2/3 mediated fibrosis during AKI-to-CKD transition
Puri B, Majumder S, Gaikwad A
Eur J Pharm Sci . 2025 Feb; 207:107044. PMID: 39956401
Acute kidney injury (AKI) is a significant clinical issue with potential long-term consequences, as even a single episode can progress to chronic kidney disease (CKD). The AKI-to-CKD transition involves complex...
24.
Enhancement of the in vitro anti-leukemic effect of the histone deacetylase inhibitor romidepsin using Poly-(D, L-lactide-co-glycolide) nanoparticles as a drug carrier
Aroonthongsawat P, Manocheewa S, Srisawat C, Punnakitikashem P, Suwanwong Y
Eur J Pharm Sci . 2025 Feb; 207:107043. PMID: 39952370
The goal of this work is to develop a delivery system for histone deacetylase inhibitor (HDACi) romidepsin (ROM) using Poly(D, L-lactide-co-glycolide) as a carrier and evaluate its anti-leukemic effects. Romidepsin-loaded...
25.
Pharmaceutical quality of herbal medicinal products and dietary supplements - a case study with oral solid formulations containing Lavandula species
Jalil B, Heinrich M
Eur J Pharm Sci . 2025 Feb; 208:107042. PMID: 39952369
The effectiveness and safety of regulated herbal medicinal products and dietary/food supplements are key areas of research. However, limited evidence exists of their pharmaceutical performance quality (including the standard in...
26.
Extracellular fungal Hsp90 represents a promising therapeutic target for combating fungal infections
Fang T, Lu H, Jiang Y
Eur J Pharm Sci . 2025 Feb; 207:107041. PMID: 39947525
Heat shock protein 90 (Hsp90) is a pivotal virulence factor in pathogenic fungi, playing a significant role in conferring drug resistance. However, due to the high amino acid sequence similarity...
27.
Impact of surface energy and surface tension on vial fogging within lyophilized drug products
Shu S, Yuan Z, Chen J, Yang Z, Zou L, Gong Y, et al.
Eur J Pharm Sci . 2025 Feb; 207:107040. PMID: 39938811
Vial fogging is a typical cosmetic cake appearance issue in lyophilized products, mostly occurring in amphiphilic protein-like freeze-dried formulations, especially antibody drug conjugate (ADC) formulations. Although fogging is currently believed...
28.
A receptor antagonist 4-(2-((6-Amino-9-ethyl-8-(furan-2-yl)-9H-purin-2-yl)amino)ethyl)phenol, a promising adenosine derivative for glioblastoma treatment
Murugesan A, Smirnov A, Alonso A, Buccioni M, Cui C, Dal Ben D, et al.
Eur J Pharm Sci . 2025 Feb; 207:107039. PMID: 39938810
Adenosine, a pervasive signaling molecule mediated by its interaction with G-protein-coupled receptor subtypes, especially the A adenosine receptor (AAR), plays a crucial role in cancer treatment. Recently, AAR targeting adenosine...
29.
Enhanced delivery of azithromycin using asymmetric polyethersulfone membrane modified with KIT-6 mesoporous material: Optimization and mechanistic studies
Samari M, Kashanian S, Zinadini S, Derakhshankhah H
Eur J Pharm Sci . 2025 Feb; 207:107038. PMID: 39933630
This study presents the development of a novel drug delivery system designed for improving the release profile and sustained delivery of azithromycin (AZI), particularly aimed at applications requiring localized infection...
30.
Synthesis of immunomodulatory biomimetic lipid polymer hybrid nanoparticles and application of zebrafish larvae in immunomodulation screening
Irabin A, Ollewagen T, Smith C, Ahmed R, Reineke J, Reijnders R, et al.
Eur J Pharm Sci . 2025 Feb; 207:107037. PMID: 39933629
Since the antibiotic golden era of the mid-20th century, there have been limited antibiotics approved, while antibiotic resistance continues to escalate disproportionately, outpacing the rate of novel antibiotic discovery. This...